Financial Performance - The company's revenue for Q3 2025 was CNY 444,521,025.75, a decrease of 26.66% compared to the same period last year[5] - The net profit attributable to shareholders was CNY -55,459,110.29, representing a decline of 169.21% year-on-year[5] - The basic earnings per share for the period was CNY -0.11, down 168.75% from the previous year[5] - Total operating revenue for the current period was CNY 1,690,175,392.80, a decrease of 22.4% compared to CNY 2,181,361,474.64 in the previous period[19] - Operating profit for the current period was CNY 129,743,948.00, a decline of 74.0% from CNY 498,107,917.74 in the previous period[20] - Net profit for the current period was CNY 126,434,775.78, a decrease of 71.3% compared to CNY 439,816,270.60 in the prior period[20] - The net profit attributable to the parent company shareholders for the current period is CNY 133,739,825.24, compared to CNY 435,935,866.11 in the previous period, representing a significant decrease[21] - The total comprehensive income for the current period is CNY 126,368,573.17, down from CNY 439,593,400.03 in the previous period[21] - The basic and diluted earnings per share for the current period are both CNY 0.28, compared to CNY 0.94 in the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,652,514,330.50, a decrease of 7.02% from the end of the previous year[5] - Total assets decreased to CNY 6,652,514,330.50 from CNY 7,154,652,043.13, reflecting a reduction of 7.0%[17] - Total liabilities decreased to CNY 1,092,031,286.57 from CNY 1,504,364,037.54, a decline of 27.4%[17] - Current assets totaled CNY 3,275,266,911.17, down 13.4% from CNY 3,785,861,965.80[17] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 52,709,195.72, down 69.59% compared to the same period last year[5] - The net cash flow from operating activities for the current period is CNY 52,709,195.72, a decrease from CNY 173,323,280.14 in the previous period[22] - The net cash flow from investing activities is CNY -292,041,488.37, compared to CNY -1,393,252,277.41 in the previous period, indicating an improvement[23] - The net cash flow from financing activities is CNY -386,059,525.34, a decrease from CNY 644,777,942.34 in the previous period[24] - The ending balance of cash and cash equivalents is CNY 202,444,818.93, down from CNY 263,576,064.78 in the previous period[24] - The company received CNY 1,752,258,544.33 in cash from sales of goods and services during the current period[22] - The company paid CNY 687,094,266.64 in cash to employees during the current period, an increase from CNY 626,141,559.34 in the previous period[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 42,360[10] - The top 10 shareholders collectively hold 31.50% of the company's total share capital, with the largest shareholder, Li Wenmei, owning 20.90%[11] - The top shareholder, Li Wenmei, holds 97,843,968 shares, while the second-largest shareholder, Wang Jihua, holds 49,594,740 shares[10] Investments and Financial Management - The company reported a significant increase in accounts receivable, which rose by 107.08% to CNY 30,205,140.02 due to increased sales settled by notes[8] - The company’s investment in other equity instruments increased by 33.96% to CNY 111,997,538.21, attributed to additional investment in Weitai Medical[8] - The company’s financial expenses increased by 97.76% to CNY 28,477,433.14, primarily due to a decrease in interest income[8] - The company recorded a 599.85% increase in investment income, amounting to CNY 13,744,980.69, due to higher financial management returns[8] Employee Compensation - The company reported a significant reduction in employee compensation liabilities, from CNY 161,555,706.01 to CNY 45,094,269.88, a decrease of 72.1%[17] Other Information - The company has not reported any new products or technologies in this earnings call[19] - The company has not engaged in any share lending or borrowing activities during the reporting period[11] - The company has no preferred shareholders or changes in preferred shareholder status during the reporting period[12] - There are no changes in the number of restricted shares during the reporting period, remaining at 13,340,000 shares[13] - The company has not undergone an audit for the third quarter financial report[25] - The company has no new strategies or significant developments reported in the financial statements[14] - There are no new product launches or technological advancements mentioned in the conference call[14]

Core Points - Wanfu Bio (300482) announced on October 21 that it will not lower the conversion price of its convertible bonds during the upcoming three-month period [1] - The board of directors decided that if the conversion price adjustment clause is triggered again after January 22, 2026, a new meeting will be held to determine whether to exercise the downward adjustment right [1] Summary by Sections - **Company Announcement** - Wanfu Bio will hold its fifth board meeting on October 21, 2025, to discuss the non-adjustment of the convertible bond conversion price [1] - The company will not propose a downward adjustment for the "Wanfu Convertible Bonds" during the specified three-month period from October 22, 2025, to January 21, 2026 [1] - **Future Considerations** - If the conversion price adjustment clause is triggered again after January 22, 2026, the board will reconvene to decide on the adjustment [1]

Group 1 - The company, Wanfu Biology, announced that its fifth board meeting will be held on October 21, 2025, via communication methods [1] - The meeting will review the proposal regarding not adjusting the conversion price of the convertible bonds [1] Group 2 - The interview with He Keng emphasizes the need to shift funding focus from excessive concentration on housing and infrastructure to enhancing investments in the livelihood sector [1]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-060 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"或"本公司"）第五届 董事会第十五次会议于 2025 年 10 月 21 日下午 15:00 在公司会议室以通讯方式 召开，会议通知于 2025 年 10 月 21 日以邮件、电话的方式向全体董事发出。会 议应到董事 7 名，实到 7 名，出席会议人数符合《公司法》和《公司章程》规 定。会议由公司董事长王继华女士主持。 经与会董事认真审议，本次会议通过以下议案： 一、审议通过《关于不向下修正可转换公司债券转股价格的议案》 根据《广州万孚生物技术股份有限公司向不特定对象发行可转换公司债券 募集说明书》（以下简称"募集说明书"）中相关条款，截至 2025 年 10 月 21 日， 公司股票在任意连续三十个交易日中至少有十五个 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、截至 2025 年 10 月 21 日，广州万孚生物技术股份有限公司（以下简称 "公司"）股票已触发"万孚转债"转股价格向下修正条款。 2、公司于 2025 年 10 月 21 日召开第五届董事会第十五次会议，审议通过 了《关于不向下修正可转换公司债券转股价格的议案》，公司董事会决定本次 不向下修正"万孚转债"转股价格，且自董事会审议通过次一交易日起未来三 个月内（即 2025 年 10 月 22 日至 2026 年 1 月 21 日），如再次触发"万孚转债" 转股价格向下修正条款，亦不提出向下修正方案。自 2026 年 1 月 22 日起算， 若再次触发"万孚转债"转股价格的向下修正条款，届时公司董事会将再次召 开会议决定是否行使"万孚转债"转股价格的向下修正权利。 | 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-061 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于不向下修正 ...

Core Viewpoint - The company announced that its stock price has been below 80% of the current conversion price for 10 trading days, which may trigger a downward adjustment of the conversion price for its convertible bonds [1] Group 1 - The stock price of Guangzhou Wanfu Biological Technology Co., Ltd. has been below the conversion price of 21.60 yuan per share since September 19, 2025 [1] - The company will hold a board meeting to decide whether to adjust the conversion price if the conditions for adjustment are triggered [1] - The company commits to timely information disclosure following the board's decision [1]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-059 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于万孚转债预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 证券代码：300482 证券简称：万孚生物 债券代码：123064 债券简称：万孚转债 转股价格：人民币 27.00 元/股 转股时间：2021 年 3 月 8 日至 2026 年 8 月 31 日 根据《广州万孚生物技术股份有限公司向不特定对象发行可转换公司债券募 集说明书》（以下简称"《募集说明书》"）中相关约定：在本次发行的可转换公司 债券存续期间，当公司股票在任意连续三十个交易日中至少有十五个交易日的收 盘价低于当期转股价格的 80%时，公司董事会有权提出转股价格向下修正方案并 提交公司股东大会表决。上述方案须经出席会议的股东所持表决权的三分之二以 上通过方可实施。 广州万孚生物技术股份有限公司（以下简称"公司"）股票自 20 ...

Core Points - Wanfu Biological announced a stock repurchase plan, with a total of 13,000 shares repurchased, representing 0.0028% of the company's total share capital [2] Summary by Category Company Actions - The company has implemented a stock repurchase through a dedicated account, utilizing centralized bidding transactions [2] - The repurchase is set to continue until September 30, 2025 [2] Financial Impact - The total number of shares repurchased is 13,000, which is a small fraction of the overall share capital [2] - The repurchase represents 0.0028% of the company's total equity [2]

Core Viewpoint - Wanfu Biological (300482.SZ) has conducted a share buyback, acquiring a total of 13,000 shares, which represents 0.0028% of the company's total share capital, in compliance with its buyback plan and relevant regulations [1] Summary by Categories - **Share Buyback Details** - The company implemented the buyback through a special account for stock repurchase via centralized bidding [1] - The highest transaction price for the repurchased shares was 21.21 yuan per share, with the lowest also being 21.21 yuan per share [1] - The total amount spent on the buyback was 275,729.00 yuan, excluding transaction fees [1]

根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，公司应当在回购期间每个月的前三个交易日内 披露截至上月末的回购进展情况，现将具体情况公告如下： 广州万孚生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 23 日 召开的第五届董事会第十四次会议审议通过了《关于回购公司股份方案的议案》， 同意公司使用自有资金以集中竞价交易方式回购公司已发行的人民币普通股股 份，用于员工持股计划和股权激励。本次用于回购股份的资金总额不低于人民币 3,000 万元且不超过人民币 6,000 万元（均包含本数），回购价格不超过人民币 34.66 元/股（含），回购实施期限自公司董事会审议通过本次回购方案之日起 6 个月内。具体内容详见公司刊登在中国证监会指定创业板信息披露网站上的相关 公告。 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、回购公司股份的进展情况 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，公司应当在每个月的前三个交 ...